Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 242

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 242
---
 |     |     | September 30, 
          2024 |   |     |     | December 31, 
         2023 |   |
|:-----------------------------------|:----|:----|--------------:|:--|:----|:----|-------------:|:--|
|                                    |     | USD |               |   |     | USD |              |   |
| Deferred tax assets:               |     |     |               |   |     |     |              |   |
| – Net operating loss carry forward |     |     |        28,441 |   |     |     |       28,441 |   |
| Less: valuation allowance          |     |     |       (28,441 | ) |     |     |      (28,441 | ) |
| Deferred tax assets, net           |     |     |             — |   |     |     |            — |   |

As of September 30,
2024 and December 31, 2023, the Company had net operating loss carry forward of $ and $. The Company believes it is less
likely than not that its operations will be able to fully utilize its deferred tax assets related to the net operating loss carry forward.
As a result, the Company provided % allowance on deferred tax assets on net operating loss.

NOTE 13 — DISAGGREGATED REVENUES

The Company’s main business operations
are to provide: (i) IVF treatment service; and (ii) surrogacy and ancillary caring services.

|                                       | Revenue from external customers | Nine months ended 
 September 30,     |      2024 |     |   |      2023 |
|:--------------------------------------|:--------------------------------|:------------------|----------:|:----|:--|----------:|
| IVF treatment service                 |                                 | $                 | 3,637,250 |     | $ | 3,162,400 |
| Surrogacy, ancillary caring and other 
 services                              |                                 |                   |   522,513 |     |   |   454,298 |
| Total revenues                        |                                 | $                 | 4,159,763 |     | $ | 3,616,698 |

F-60 NEWGENIVF GROUP LIMITED
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBER 30, 2024 AND 2023
(Stated